Introduction
============

Leukemia, a malignant disease affecting blood cells, usually begins in the bone marrow and is characterized by an aberrant accumulation of abnormal white blood cells. Leukemia can be clinically and pathologically subdivided into four main types: acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML), as well as many less common types ([@B42]). The treatment of leukemia is complicated and is influenced by the age and overall health of an affected patient as well as by their type of leukemia, in addition to other factors. However, chemotherapy remains one of the major therapeutic approaches for leukemia.

Both AML and CML are myeloid or myelogenous leukemias, and the initial cancerous changes associated with these cancers affect certain blood-forming cells in the bone marrow. Currently, bone marrow transplantation/allogeneic stem cell transplantation is the only curative treatment for CML ([@B12]). TKIs that target BCR-ABL are the standard treatment for CML. Imatinib mesylate, a first-generation TKI ([@B22]), has produced excellent clinical results in terms of achieving high remission rates and improving prognosis ([@B20]; [@B2]). New second- and third- generation TKIs, such as dasatinib, nilotinib, and bosutinib, exhibit superior inhibitory activity against BCR-ABL compared to imatinib. Although TKIs are extensively used, serious drug-drug interactions and emerging resistance of CML cells to TKIs through multiple mechanisms has limited their clinical application ([@B43]).

AML is the most common acute leukemia in adult patients. This type of leukemia progresses rapidly and may be lethal within weeks or months. Based on the cytogenetic/genetic features of AML, and according to the 2008 revised WHO classification system, patients can be broadly classified into three different risk groups. Treatment strategies and prognoses vary among these subtypes and are further influenced by patient-specific factors ([@B13]; [@B47]). All AML subtypes, except for acute promyelocytic leukemia (APL), are typically treated with induction chemotherapy using a "3+7" combination of daunorubicin and cytarabine ([@B7]; [@B47]). Treatment with all-trans retinoic acid, which can effectively induce APL cell differentiation, can achieve complete remission in almost all APL patients ([@B6]). Conversely, although treatment strategies for AML have substantially progressed in recent decades, effective therapies for non-APL subtypes of AML are still urgently needed.

Tumor cells usually have a more active metabolism than normal cells to maintain their rapid growth and escape from cell death ([@B15]). Leukemia cells undergo many pathological changes compared to normal blood cells. Therefore, the identification of phytocompounds from medicinal or edible plants that affect multiple intracellular targets may lead to the discovery of a novel, effective and multifunctionalanti-leukemia drug or prodrug.

*Elephantopus mollis* (EM) belongs to the Asteraceae family and is used as a folk medicine in China. EM possesses multiple pharmacological activities, including anticancer activity ([@B37]; [@B33], [@B34]), anti-protozoal activity ([@B10]), melanogenesis inhibition activity ([@B16]), bone regenerative activity ([@B32]), and hepatoprotective activity ([@B25]). However, whether EM is an efficacious treatment option for human AML and CML remains unknown.

In this study, we investigated the anti-leukemia properties and associated molecular mechanisms of EM23, a natural sesquiterpene lactone isolated from EM, in the K562 and HL-60 human CML and AML cell lines. Mechanistically, we demonstrated that EM23 inhibited the mammalian Trx system, interfered with cellular redox homeostasis and resulted in ROS-dependent apoptosis by regulating complex signaling pathways, including those governed by ASK1, MAPK, and NF-κB.

Materials and Methods {#s1}
=====================

Cell Culture and Reagents
-------------------------

The human CML cell line K562, the human APL cell line HL-60, human liver cell line HL-7702 and mouse embryonic fibroblast cell line NIH/3T3 (NIH/swiss) were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). K562 and HL-60 cells were cultured in RPMI 1640 medium (Life Technologies, Grand Island, NY, USA). HL-7702 and NIH/3T3 cells were grown in DMEM medium (Life Technologies, Grand Island, NY, USA). All cell lines were grown in specific media supplemented with 10% fetal bovine serum (FBS, Gibco), 100 U/mL penicillin and 100 μg/mL streptomycin (Invitrogen, Carlsbad, CA, USA). The cells were grown in a 5% CO~2~ humidified atmosphere in incubators maintained at 37°C.

EM23 (**Figure [1A](#F1){ref-type="fig"}**) was isolated and purified from EM by our group. The chemical structure of EM23 was identified by ^1^H-NMR and ^13^C-NMR spectra data as described in our previous study ([@B24]). A stock solution of EM23 was dissolved in DMSO at concentration of 100 mM and diluted to the indicated final concentration in culture medium. DMSO was diluted to 0.1% in medium as a vehicle control.

![**EM23 inhibits cell proliferation and cell cycle progression. (A)** Chemical structure of EM23. **(B)** Effects of EM23 on human myeloid leukemia cell proliferation. K562 and HL-60 cells were treated with various concentrations of EM23 for 48 and 72 h, respectively. Cell viability was measured using a CCK-8 assay. **(C)** Cytotoxic effects of EM23 on normal mammalian cells. HL-7702 and NIH/3T3 cells were treated with various concentrations of EM23 for 48 h. Cell viability was measured using a CCK-8 assay. **(D)** Effects of EM23 on cell cycle distribution. Following treatment with EM23 for 48 h, cells were fixed and stained with PI solution. Cell cycle distribution was measured by flow cytometry. All of data are presented as the mean ± SD of at least three independent experiments. ^∗^*P* \< 0.05 and ^∗∗^*P* \< 0.01.](fphar-07-00077-g001){#F1}

The reagents DAPI, DCFH-DA, PI, JC-1, and NAC were purchased from Sigma Chemical Co. (St. Louis, MO, USA). ERK inhibitor FR180204 was purchased from Merck Millipore (Bellerica, MA, USA). A Pierce^TM^ BCA Protein Assay Kit was obtained from Thermo Fisher Scientific (Rockford, IL, USA). TNF-α was obtained from Sino Biological Inc. (Beijing, China). A CCK-8, a TUNEL Apoptosis Detection Kit, dithiothreitol (DTT), a Nuclear and Cytoplasmic Extraction Kit, RIPA buffer and RNase were purchased from Beyotime (Shanghai, China). Phosphatase inhibitor cocktail tablets and protease inhibitor cocktail tablets were supplied by Roche (Mannheim, Germany). All other chemicals and solvents were of reagent or HPLC grade.

Primary antibodies against TrxR, Trx, ASK1, p-ASK1 (Thr845), and Lamin B1 were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). GAPDH, β-actin, caspase 3, caspase 9, cleaved-caspase 3, cleaved-caspase 9, cleaved PARP, p-p38 (Thr180/Tyr182), p-ERK1/2 (Thr202/Tyr204), p-JNK (Thr183/Tyr185), p38, ERK1/2, JNK, p-NF-κB p-p65 (Ser536), NF-κB p65, IκBα, anti-mouse, and anti-rabbit horseradish peroxidase-conjugated secondary antibodies were purchased from Cell Signaling Technology (CST, Beverly, MA, USA). Alexa Fluor^®^ 568 phalloidin and Alexa Fluor^®^ 488 anti-rabbit fluorescent secondary antibodies were purchased from Life Technologies (Grand Island, NY, USA).

Cell Proliferation Analysis
---------------------------

A CCK-8 assay was used to detect EM23-mediated inhibition of cellular proliferation. Cells in suspension were plated in 96-well plates at a density of 1 × 10^4^ cells/well. Following this, the cells were treated with either vehicle (0.1% DMSO) or EM23. The highest concentration of EM23 used was 100 μM; additional concentrations were tested following two-fold serial dilutions. The cells were treated for 48 h and then 10 μL CCK-8 solution was added to each well, and the plate was incubated for an additional 4 h. The absorbance of the plate was measured at 450 nm using a microplate reader (Bio-Rad; Hercules, CA, USA), and the IC50 values for the different treatment conditions were calculated using Origin 8 software (OriginLab, Northampton, MA, USA).

Cell Cycle Analysis
-------------------

K562 (2 × 10^5^ cells/mL) and HL-60 (3 × 10^5^ cells/mL) cells were seeded into 6-well plates and then treated with vehicle or EM23 for 48 h. Following this, the cells were collected, washed twice with PBS, and fixed in cold 70% ethanol (--20°C) overnight. The ethanol was then carefully removed by centrifugation to avoid cell loss, and the cells were resuspended in 1 mL staining reagent (100 mg/mL RNase and 50 mg/mL PI) and kept in darkness for 35 min at room temperature. Cell cycle analysis was accomplished using flow cytometry (BD FACSCalibur, Franklin Lakes, CA, USA) with a wave length of 605 nm.

Apoptosis Detection via Annexin-V-FITC/PI Assay
-----------------------------------------------

K562 (2 × 10^5^ cells/mL) and HL-60 (3 × 10^5^ cells/mL) cells were plated in 6-well plates during the log phase of growth and then treated with either vehicle or the indicated concentrations of EM23 for 48 h. The treated cells were harvested by centrifugation at room temperature and washed twice with ice-cold PBS. Following this, the cells were stained with Annexin-V-FITC/PI (KeyGEN; Nanjing, China) according to the manufacturer's instructions and analyzed via flow cytometry.

Western Blotting Analysis
-------------------------

K562 and HL-60 cells were harvested and washed with PBS after treatment with EM23 according to the specific experimental design. Following this, the cells were lysed in RIPA buffer containing 0.5 M DTT, 0.1 M PMSF, 20× protease inhibitor cocktail, and 20× phosphatase inhibitor cocktail for 30 min on ice, and then centrifuged at 12000 *g* at 4°C for 15 min. The resultant supernatants, which contained total cellular protein, were collected, and nuclear proteins were extracted using a nuclear and cytoplasmic extraction kit. The protein concentration was measured using a BCA protein assay kit. Equal amounts of protein (30 μg) were separated via 10--15% gradient SDS-PAGE and transferred to PVDF membranes (Millipore, USA). The membranes were blocked with 5% BSA at room temperature for 1 h, incubated with primary antibodies for at least 16 h at 4°C, and then washed and incubated with HRP-conjugated secondary antibodies at room temperature for 1 h. Protein bands were visualized using enhanced chemiluminescence detection reagents (Bio-Rad, USA). The resulting images were scanned using a scanner (Epson V330 Photo, Japan).

TUNEL and DAPI Co-staining
--------------------------

K562 and HL-60 cells were treated with either vehicle or EM23 for 48 h, collected into Eppendorf tubes, and washed twice with PBS. Following 4% paraformaldehyde fixation, the cells were permeabilized with 0.2% Triton X-100 in PBS. Next, the cells were stained with TUNEL reaction mixture and DAPI, after which they were washed again with ice-cold PBS. The stained cells were resuspended to a specific cell density and examined under a confocal laser scanning microscope (Zeiss LSM 510, Germany) for evidence of nuclear fragmentation.

Immunofluorescent Cell Staining
-------------------------------

K562 (2 × 10^5^ cells/mL) and HL-60 (3 × 10^5^ cells/mL) cells were seeded in 6-well plates and then co-treated with vehicle or EM23 with or without TNF-α (1 ng/mL) for 1 h. Following this, the cells were collected, and subsequent operations were performed in Eppendorf tubes. First, the cells were washed with ice-cold PBS. Following this, the cells were fixed in 4% paraformaldehyde for 15 min at room temperature and permeabilized with 0.2% Triton X-100 in PBS. After being rinsed with PBS, the cells were blocked with 5% BSA and incubated with an anti-p65 primary antibody and an anti-rabbit fluorescent secondary antibody. Following this, the cells were counterstained with phalloidin and DAPI, washed again with ice-cold PBS and resuspended to a specific cell density. To visualize the nuclear translocation of p65, the above-treated cells were placed into a confocal 35-mm clear cover glass-bottom petri-dish and then viewed and photographed using a confocal laser scanning microscope. The collected images were processed using the manufacturer's software.

Evaluation of MMP
-----------------

Mitochondrial membrane potential was measured using JC-1 dye according to the manufacturer's instructions. Cells treated with the indicated experimental conditions were harvested and then incubated with JC-1 dye (10 μg/mL) in the dark for 20 min at 37°C. Following this, the cells were washed with ice-cold PBS and analyzed by flow cytometry.

Determination of Cellular ROS Generation
----------------------------------------

Intracellular ROS levels were measured using a DCFH-DA assay after EM23 treatment. Briefly, after treatment with EM23 for1--4 h, K562, and HL-60 cells were incubated with 10 μM DCF-DA at 37°C for 30 min and then washed twice and resuspended in PBS. Fluorescence intensity was measured by flow cytometry, and the percentages of fluorescence-positive cells were proportional to the ROS levels within the cell cytosol.

Statistical Analysis
--------------------

All data are expressed as the mean ± standard deviation (SD) of three independent experiments. Statistical significance was assessed using Student's *t*-test (for comparisons of two treatment groups) or one-way ANOVA (for comparisons of three or more groups). *P*-values \< 0.05 were considered statistically significant.

Results
=======

EM23 Inhibits the Proliferation of K562 and HL-60 Leukemia Cells
----------------------------------------------------------------

The chemical structure of EM23 is shown in **Figure [1A](#F1){ref-type="fig"}**. A CCK-8 assay was used to evaluate the ability of EM23 to inhibit leukemia cell proliferation. **Figure [1B](#F1){ref-type="fig"}** shows that EM23 suppressed the proliferation of K562 and HL-60 cells in a dose-dependent manner. After 48 h of treatment with EM23, the IC~50~ values for K562 and HL-60 cells were 10.8 and 1.9 μM, respectively. When the treatment time was extended to 72 h, EM23 showed more significant proliferation inhibitory activities, with IC~50~ values of 6.3 and 1.4 μM for K562 and HL-60 cells, respectively.

We also examined the effects of EM23 on the proliferation of normal mammalian HL-7702 and NIH/3T3 cells. As shown in **Figure [1C](#F1){ref-type="fig"}**, EM23 exhibited lower proliferation inhibitory activities in HL-7702 and NIH/3T3 cells as compared to those in K562 and HL-60 leukemia cells. The IC~50~ values of EM23 for HL-7702 and NIH/3T3 cells were 40.4 and 25.6 μM, respectively, which were approximately 4-fold and 2-fold higher than that of for K562 cells, and 21-fold and 13-fold higher than that of for HL-60 cells, respectively. In addition, the rate of cell viability was above 85% when HL-7702 and NIH/3T3 cells were treated with EM23 at 8 μM for 48 h.

EM23 Delays Cell Cycle Progression in K562 and HL-60 Cells
----------------------------------------------------------

To elucidate whether EM23-mediated decreases in K562 and HL-60 cell proliferation were associated with changes in cell cycle progression, the cell cycle phase distributions of EM23-treated cells were analyzed by flow cytometry. As shown in **Figure [1C](#F1){ref-type="fig"}**, treatment with increasing concentrations of EM23 for 48 h decreased the G~0~/G~1~ phase DNA content from 42.6 to 35.6%, whereas the G~2~/M DNA content increased from 5.1 to 12.5% in K562 cells, which dose-dependently accumulated the cells in G2/M phase. In HL-60 cells, treatment with 4 μM EM23 increased the number of cells in S phase by 29.5%, while the number of cells in G~0/~G~1~ phase decreased by 23.1% compared with the control (**Figure [1D](#F1){ref-type="fig"}**).

EM23 Induces Apoptosis and Caspase Activation in K562 and HL-60 Cells
---------------------------------------------------------------------

To further investigate the role of EM23 in the induction of apoptotic cell death, K562 and HL-60 cells were treated with the indicated concentrations of EM23 for 48 h, and cell apoptosis was assessed via Annexin-V-FITC/PI FACS analysis. Notably, both cell lines showed significant dose-dependent increases in apoptosis ratios following treatment with EM23 (**Figure [2A](#F2){ref-type="fig"}**). At an EM23 concentration of 8 μM, the apoptosis ratios were 62.6% for K562 cells. In HL-60 cells, treatment with 4 μM EM23 increased the percentage of apoptotic cells by 46.5% compared with the control (**Figure [2A](#F2){ref-type="fig"}**). Furthermore, TUNEL-DAPI co-staining revealed that the EM23-treated cells exhibited enhanced apoptotic features, such as DNA fragmentation and nuclear condensation (**Figure [2B](#F2){ref-type="fig"}**).

![**EM23 induced cell apoptosis. (A)** Effects of EM23 on the induction of apoptosis as measured by flow cytometry. K562 and HL-60 cells were treated with EM23 for 48 h, and the apoptotic cell rate was analyzed after Annexin-V-FITC/PI staining. The data are presented as the mean ± SD of three independent experiments. ^∗^*P* \< 0.05 and ^∗∗^*P* \< 0.01. **(B)** Representative images of DNA fragmentation and nuclear condensation in K562 and HL-60 cells exposed to EM23. Nuclei were detected by TUNEL and DAPI staining. All images shown are representative of three independent experiments. **(C)** Western blotting analysis of caspase 9, cleaved caspase 9, caspase 3, cleaved caspase 3, and cleaved PARP (89 kDa) expression; β-actin served as an internal control. The data shown are representative of three independent experiments.](fphar-07-00077-g002){#F2}

We next analyzed caspase activation and PARP cleavage in EM23-treated cells. As shown in **Figure [2C](#F2){ref-type="fig"}**, the levels of initiator caspases 9 and 3 significantly decreased as the concentration of EM23 increased. Additionally, the levels of cleaved caspase 9 and 3 dose-dependently increased with EM23 treatment. PARP, a DNA-repair enzyme, serves as a substrate for caspase 3 ([@B30]). We next examined PARP degradation following EM23 treatment. As shown in **Figure [2C](#F2){ref-type="fig"}**, EM23 treatment led to specific proteolytic cleavage of PARP, as indicated by the presence of 116 to 89 kDa PARP fragments in K562 and HL-60 cells. These results suggest that caspase activation and PARP cleavage may underlie EM23-mediated apoptosis in K562 and HL-60 cells.

EM23 Induces a Loss in MMP
--------------------------

The loss of MMP (Δψ~m~) is a vital cellular event during the process of intrinsic apoptosis. Therefore, we measured variations in Δψ~m~ using a JC-1 MMP assay to monitor mitochondrial status in EM23-treated K562 and HL-60 cells. As shown in **Figure [3A](#F3){ref-type="fig"}**, EM23 treatment clearly disrupted Δψ~m~ in both cell lines in a dose-dependent manner. The proportions of green-fluorescent cells within K562 and HL-60 cell populations increased by 36.2 and 55.5%, respectively, following treatment with 8 and 4 μM EM23, demonstrating that EM23 led to MMP disruption in both cell lines.

![**EM23 interfered with cellular redox homeostasis. (A)** Flow cytometry analysis of MMP based on JC-1 staining. Cells were treated with EM23 for 48 h and stained with JC-1. The cells showing a loss of MMP were gated. Cells were exposed to the MMP disrupter carbonyl cyanide 3-chlorophenylhydrazone (CCCP, 10 μM) for 20 min as a positive control. All data are presented as the mean ± SD of three independent experiments. ^∗^*P* \< 0.05 and ^∗∗^*P* \< 0.01. **(B)** EM23 induced ROS production in K562 and HL-60 cells. Cells were treated with 2 μM EM23 for 1--4 h, stained with DCFH-DA for 20 min, and analyzed for fluorescence by flow cytometry. All data are presented as the mean ± SD of three independent experiments. ^∗^*P* \< 0.05 and ^∗∗^*P* \< 0.01. **(C)** Effects of EM23 on the expression levels of Trx and TrxR. K562 and HL-60 cells were treated with EM23 for 48 h and then subjected to western blotting. β-actin was used as an internal control. The data shown are representative of three independent experiments.](fphar-07-00077-g003){#F3}

EM23 Increases Cellular ROS Levels and Suppresses Trx System
------------------------------------------------------------

To investigate whether EM23-mediated apoptosis was related to the presence of ROS, we examined intracellular ROS production in EM23-treated K562 and HL-60 cells using the fluorescent probe DCFH-DA. As shown in **Figure [3B](#F3){ref-type="fig"}**, compared to the control, intracellular ROS levels increased by over twofold in both cell lines following exposure to EM23 for 2 h, indicating that ROS accumulation occurred in both K562 and HL-60 cells in response to treatment with EM23. Interestingly, continuous incubation with EM23 for 4 h led to decreased ROS levels in both cell lines relative to those measured after 2 h of treatment.

To further investigate the role of ROS generation in EM23-mediated apoptosis, both cell lines were pretreated with the ROS scavenger NAC. Flow cytometry analysis demonstrated that EM23-mediated apoptosis and accumulation of cells in G~2~/M or S phase were almost entirely rescued by NAC (**Figures [4A,B](#F4){ref-type="fig"}**). As shown in **Figure [4C](#F4){ref-type="fig"}**, pretreatment with NAC also significantly inhibited EM23-mediated DNA fragmentation and nuclear condensation based on TUNEL-DAPI co-staining. These results suggest that ROS accumulation was required for apoptotic cell death in EM23-treated K562 and HL-60 cells.

![**NAC reversed EM23-mediated apoptosis and cells accumulation. (A)** The induction of apoptosis in K562 and HL-60 cells following treatment with EM23 was rescued following treatment with NAC. K562 and HL-60 cells were pretreated with 5 mM NAC for 1 h, followed by treatment with 8 and 4 μM EM23 for 48 h, respectively. Next, the treated cells were stained with Annexin-V-FITC/PI and analyzed by flow cytometry. All data are presented as the mean ± SD of three independent experiments. Bars with different characters indicate significant differences. ^∗^*P* \< 0.05 and ^∗∗^*P* \< 0.01 compared to control; ^\#^*P* \< 0.05 and ^\#\#^*P* \< 0.01 compared to NAC+EM23. **(B)** NAC inhibited EM23-mediated cell cycle redistribution. K562 and HL-60 cells were pretreated with 5 mM NAC for 1 h, followed by treatment with 8 and 4 μM EM23 for 48 h, respectively. The cell cycle phase distributions of the EM23-treated cells were analyzed by flow cytometry. All data are presented as the mean ± SD of three independent experiments. Bars with different characters indicate significant differences. ^∗^*P* \< 0.05 and ^∗∗^*P* \< 0.01 compared to control; ^\#^*P* \< 0.05 and ^\#\#^*P* \< 0.01 compared to NAC+EM23. **(C)** NAC reduced the morphological changes caused by EM23. K562 and HL-60 cells were treated with 16 and 8 μM, respectively, and then subjected to TUNEL-DAPI co-staining and examined under a confocal laser scanning microscope. All images shown are representative of three independent experiments that produced similar results.](fphar-07-00077-g004){#F4}

The Trx system, one of the major intracellular antioxidant systems, is integral for maintaining a balanced intracellular redox state ([@B5]). The effects of EM23 on Trx and TrxR expression were examined in K562 and HL-60 cells. As shown in **Figure [3C](#F3){ref-type="fig"}**, the expression levels of both Trx and TrxR were dose-dependently down-regulated by EM23 in K562 and HL-60 cells. These results suggest that EM23 may increase cellular ROS levels by inhibiting the Trx system.

ASK1- and MAPK-Mediated Signaling Pathways in EM23-Treated Cells
----------------------------------------------------------------

ASK1 is activated by various types of stress, including the accumulation of ROS. The reduced form of Trx is an endogenous inhibitor of ASK1. When Trx is oxidized, it dissociates from ASK1, which is then activated by the autophosphorylation of Thr845 in its kinase domain, leading to the downstream activation of the JNK and p38 MAPK pathways ([@B27]). As shown in **Figure [5A](#F5){ref-type="fig"}**, EM23 activated endogenous ASK1 through the phosphorylation of its Thr845 residue in a time-dependent and dose-dependent manner in K562 and HL-60 cells. It is interesting that ASK1 expression dose-dependently and time-dependently decreased following treatment with EM23 (**Figure [5A](#F5){ref-type="fig"}**). Next, we investigated how treatment with EM23 affected the phosphorylation statuses of three different MAPKs (p38, JNK, and ERK1/2) in K562 and HL-60 cells by western blotting analysis. As shown in **Figure [5B](#F5){ref-type="fig"}** p38 and JNK were time-dependently activated in both cell lines following treatment with 8 μM EM23. The maximum activation of JNK by EM23 occurred within 3 h of treatment, followed by a progressive decline after 6 h (**Figure [5B](#F5){ref-type="fig"}**). A similar progression of p38 activation was also observed in EM23-treated K562 cells, while continuous activation of p38 was observed in EM23-treated HL-60 cells (**Figure [5B](#F5){ref-type="fig"}**). K562 and HL-60 cells showed different ERK1/2 phosphorylation profiles following EM23 treatment (**Figure [5B](#F5){ref-type="fig"}**). Treatment of K562 cells with 8 μM EM23 markedly increased ERK1/2 phosphorylation within 1 h, followed by sustained activation of ERK1/2 within 12 h. Unlike in K562 cells, no obvious activation of ERK1/2 was observed in HL-60 cells treated with EM23 for 12 h (**Figure [5B](#F5){ref-type="fig"}**). The ERK inhibitor FR180204 was further used to clarify the role of ERK in EM23-mediated apoptosis. As shown in **Figure [5C](#F5){ref-type="fig"}**, co-incubation of EM23 and FR180204 significantly increased the viability of K562 cells as compared to the cells only treated with EM23. While there was no obvious change in cellular viability when HL-60 cells were co-treated with EM23 and FR180204. These results indicated that MAPK activation might be involved in EM23-mediated apoptosis.

![**Effects of EM23 on ASK1 and p38/JNK/ERK MAPK activation. (A)** K562 and HL-60 cells were treated with 0, 2, 4, and 8 μM EM23 for 48 h or treated with 8 μM EM23 for 0, 0.5, 1, 3, 6, and 12 h. The expression levels of ASK1 and p-ASK1 were analyzed by western blotting analysis. β-actin was used as an internal control. **(B)** K562 and HL-60 cells were exposed to 8 μM EM23 for 0, 0.5, 1, 3, 6, and 12 h and then the phosphorylation levels of p38, JNK, and ERK1/2 were detected by western blotting. All protein levels were normalized to the level of β-actin. The data shown are representative of three independent experiments. **(C)** Effects of ERK inhibitor FR180204 on EM23-mediated proliferation inhibitory activities. K562 and HL-60 cells were pre-treated with 5 and 2.5 μM FR180204, respectively. Then the cells were incubated with various concentrations of EM23 for 48 h. Cell viability was measured using a CCK-8 assay. The data shown are the mean ± SD of at least three independent experiments. ^∗^*P* \< 0.05 and ^∗∗^*P* \< 0.01.](fphar-07-00077-g005){#F5}

To further determine whether ROS production can trigger ASK1 and MAPK activation following EM23 treatment, cells were pretreated with 5 mM NAC for 1 h and then treated with EM23 and subjected to western blotting analysis. As shown in **Figures [6A,B](#F6){ref-type="fig"}**, NAC blocked EM23-mediated activation of ASK1, p38 and JNK in K562 and HL-60 cells. Similarly, EM23-mediated promotion of ERK1/2 phosphorylation in K562 cells was significantly suppressed following NAC pretreatment, while ERK1/2 phosphorylation in HL-60 cells was unaltered, which was consistent with previous results (**Figure [6B](#F6){ref-type="fig"}**). These results further support the important role of ROS in EM23-mediated activation of ASK1/MAPK signaling pathways.

![**NAC reversed EM23-mediated increases in ASK1 and MAPK phosphorylation. (A)** K562 and HL-60 cells were treated with vehicle, 5 mM NAC, or 8 μM EM23 for 12 h. Cells were also pretreated with 5 mM NAC for 1 h, followed by treatment with 8 μM EM23 for 12 h. Protein levels of ASK1 and p-ASK1 were analyzed by western blotting. **(B)** K562 and HL-60 cells were treated with vehicle, 5 mM NAC, and 8 μM EM23 for 3 h. Cells were also pretreated with 5 mM NAC for 1 h, followed by treatment with 8 μM EM23 for 3 h. Total protein extracts from treated cells were submitted to western blotting for detection of p38, p-p38, JNK, p-JNK, ERK1/2, and p-ERK1/2. β-actin was used as an internal control. All data shown are representative of three independent experiments.](fphar-07-00077-g006){#F6}

EM23 Suppresses TNF-α-Mediated NF-κB Activation
-----------------------------------------------

Reactive oxygen species interacts with NF-κB signaling pathways in many ways ([@B29]). Therefore, we investigated the effects of EM23 on TNF-α-mediated NF-κB activation via immunofluorescent staining and western blotting analysis. As shown in **Figure [7A](#F7){ref-type="fig"}**, p65 was primarily distributed throughout the cytoplasm of the control cells. The addition of TNF-α caused p65 to undergo nuclear translocation, which was significantly blocked following EM23 treatment in both K562 and HL-60 cells (**Figures [7A,B](#F7){ref-type="fig"}**). Moreover, EM23 treatment significantly suppressed TNF-α-mediated phosphorylation of p65 (**Figure [7B](#F7){ref-type="fig"}**). In the cytoplasm, TNF-α stimulation decreased levels of cytoplasmic IκBα, while EM23 treatment significantly reversed TNF-α-mediated IκBα degradation, although not completely (**Figure [7C](#F7){ref-type="fig"}**). These results indicate that EM23 suppresses TNF-α-mediated NF-κB activation.

![**Inhibitory effects of EM23 on TNF-α-mediated NF-κB activation. (A)** Immunofluorescence analysis of p65 localization. K562 and HL-60 cells were treated with vehicle or EM23 for 1 h and then stimulated with 1 nM TNF-α for 30 min. The cells were stained with DAPI (blue), FITC-labeled anti-p65 antibody (green) and phalloidin (for F-actin labeling, red). All data shown are representative of three independent experiments. **(B)** Effects of EM23 on TNF-α-mediated translocalization and phosphorylation of p65. K562 and HL-60 cells were co-incubated with 8 μM EM23 and 1 nM TNF-α for the indicated times. Nuclear extracts were prepared and submitted to western blotting for the detection of p65 and p-p65. Lamin B1 was used as a loading control. All data shown are representative of three independent experiments. **(C)** Effect of EM23 on TNF-α-mediated degradation of IκBα. K562 and HL-60 cells were co-incubated with 8 μM EM23 and 1 nM TNF-α for the indicated times. Cytoplasmic extracts were prepared and submitted to western blotting for the detection of IκBα. β-actin was used as a loading control. All data shown are representative of three independent experiments. **(D)** EM23 enhanced TNF-α-mediated cytotoxicity. K562 and HL-60 cells were, respectively, incubated with 4 and 2 μM EM23 for 1 h, followed by treatment with 1 nM TNF-α for 24 h. The cytotoxicity of the combined treatment of EM23 and TNF-α was detected by CCK-8 assay. All data are presented as the mean ± SD of three independent experiments. Bars with different characters indicate significant differences. ^∗^*P* \< 0.05 and ^∗∗^*P* \< 0.01 compared to control; ^\#^*P* \< 0.05 and ^\#\#^*P* \< 0.01 compared to TNF-α+EM23.](fphar-07-00077-g007){#F7}

Next, we examined the effects of combined treatment with TNF-α and EM23 on the proliferation of K562 and HL-60 cells using a CCK-8 assay. As shown in **Figure [7D](#F7){ref-type="fig"}**, treating cells with a combination of TNF-α and EM23 resulted in higher cytotoxicity, with inhibition rates ranging from 20.0 to 45.2% and from 18.1 to 37.5% in K562 and HL-60 cells, respectively. These results indicated that EM23 is a potent NF-κB inhibitor and that this effect is enhanced by TNF-α-mediated cytotoxicity.

Discussion
==========

Natural products, in addition to their traditional uses, have served as important sources of bioactive compounds that have played significant roles in medical discovery and development processes ([@B31]; [@B44]). The genus *Elephantopus*, which belongs to the Asteraceae family, has recently attracted a great deal of interest due to its diverse pharmacological activities. Several species of *Elephantopus* contained sesquiterpene lactones have been reported to exert cytotoxicity and possess potential anticancer activities. Deoxyelephantopin and isodeoxyelephantopin, two germacranolidese squiterpene lactones, are components of extracts of *Elephantopus scaber* L.. Isodeoxyelephantopin has been reported to suppress NF-κB, potentiate apoptosis, inhibit invasion and abolish osteoclastogenesis in leukemia KBM-5 cells ([@B21]). Deoxyelephantopin was found to inhibit TS/A tumor growth and lung metastasis and double survival time in mice bearing mammary tumors ([@B19]). Some of other sesquiterpene lactones from the other Asteraceae plants, such as thapsigargin, artemisinin and parthenolide, have also been reported to have anticancer activities *in vivo*. Thapsigargin derivation G-202 is used for treating breast, kidney and prostate cancer in phase I study ([@B11]). Artemisnin and its derivations, artesunate and artemether, are being tested in phase I/II clinical trials for the treatment of breast, colorectal, and non-small cell lung cancers ([@B1]; [@B48]). A parthenolide analog dimethylamino-parthenolide is now in clinical phase I against AML, ALL, and other blood cancers ([@B14]; [@B11]). These findings provide clues for potential therapeutic application of EM23 as anti-leukemia agents in clinic. It is worthy further investigating the effect of EM23 on AML and CML *in vivo* in next study.

Apoptosis, a programmed form of cell death, involves the degradation of cellular constituents by a group of cysteine proteases called caspases. Caspase activation occurs through two main molecular pathways, known as the extrinsic and the intrinsic apoptotic pathways ([@B3]). The intrinsic apoptotic pathway is characterized by mitochondrial permeabilization, causing the release of pro-apoptotic proteins into the cytosol ([@B28]). Indeed, we found that EM23 significantly decreased Δψ~m~ in K562 and HL-60 cells (**Figure [3A](#F3){ref-type="fig"}**) and up-regulated caspase signaling cascades (caspases 9 and 3), which resulted in the activation of the downstream cellular death substrate PARP (**Figure [2C](#F2){ref-type="fig"}**). These findings indicate that EM23 may induce apoptosis through the intrinsic apoptotic pathway.

Excessive intracellular production of ROS is known to induce apoptosis ([@B35]). The mitochondrial respiratory chain (electron transport complexes) is a major source of intracellular ROS generation ([@B35]). In the current study, EM23 induced obvious mitochondrial dysfunction and markedly increased intracellular ROS levels in K562 and HL-60 cells. Cellular ROS generation played a vital role in EM23-mediated apoptosis and accumulation of cells in G2/M or S phase in both cell lines, and co-treatment with EM23 and the reducing agent NAC, which quenches ROS, almost completely reversed these effects (**Figure [4](#F4){ref-type="fig"}**). These results indicate that EM23-mediated apoptosis in K562 and HL-60 cells might be governed by ROS-mediated mechanisms.

The Trx system, a ubiquitous oxidoreductase system that is overexpressed in various tumor types, has important roles in reducing enzymes and maintaining intracellular protein thiol redox balance ([@B8]). The mammalian TrxR protein contains a highly reactive active selenocysteine residue that is susceptible to electrophilic compounds and has been identified as a novel chemotherapeutic target for anticancer drug development ([@B26]). Recent studies have revealed that redox-regulating mechanisms, such as the Trx system, represent important targets for the treatment of malignancies ([@B39]). Disruption of the Trx system by EM23 may interfere with intracellular redox balance and lead to the accumulation of ROS, which subsequently initiates apoptosis in K562 and HL-60 cells.

Trx target proteins are involved in various specific pathways associated with the regulation of apoptosis. ASK1, a MAPKKK family member, is tightly controlled by Trx and acts as a major contributor in regulating ROS-mediated apoptosis through the activation of the JNK and p38 signaling pathways ([@B36]). Our results demonstrated that EM23 treatment increased the phosphorylation of ASK1 at Thr845 (**Figure [5A](#F5){ref-type="fig"}**), which further phosphorylated the downstream MAPKs JNK and p38 (**Figure [5B](#F5){ref-type="fig"}**), suggesting that EM23 may activate the ASK1-JNK/p38 signaling axis in a ROS-dependent manner to exert its pro-apoptotic effects. In addition, following co-treatment with EM23 and NAC, the phosphorylation levels of ASK1, p38 and JNK were notably lower than those following EM23 treatment alone (**Figure [6](#F6){ref-type="fig"}**). These results are consistent with the full reversion of EM23-mediated apoptosis that was found following pretreatment with NAC. Our results indicated that EM23-mediated ROS accumulation was an important signaling intermediate in ASK1-dependent apoptosis.

It has been well established that increases in ROS levels are effective inducers of MAPK-mediated apoptosis ([@B9]). As shown in **Figure [6B](#F6){ref-type="fig"}**, downstream MAPK (p38, JNK and ERK1/2) pathways became activated following EM23 treatment in K562 cells. In HL-60 cells, treatment with EM23 also led to significant activation of p38 and JNK; however, there was no obvious increase in ERK1/2 phosphorylation during the treatment (**Figure [6B](#F6){ref-type="fig"}**). Our results are in agreement with other studies reporting that compounds that cause ROS generation do not necessarily lead to increases in ERK1/2 phosphorylation in treated HL-60 cells ([@B40]; [@B45]). It is well documented that the activation of ERK1/2 generally promotes cell survival. However, depending on cell type and stimulus, ERK1/2 also can mediate pro-apoptotic functions ([@B4]; [@B23]). Our results indicated that ERK1/2 activation in K562 cells may contribute to EM23-mediated apoptosis (**Figure [5C](#F5){ref-type="fig"}**).

NF-κB, one of major chemoresistance-related anti-apoptotic factors ([@B46]), is frequently up-regulated in human chronic and AML ([@B18]). Trx plays dual and opposing roles in the regulation of NF-κB: in the cytoplasm, Trx blocks IκBα degradation, thereby inhibiting NF-κB activation ([@B38]), whereas in the nucleus Trx enhances NF-κB transcriptional activity by enhancing its ability to bind DNA ([@B17]; [@B41]). In the current study, it is possible that EM23 inhibited the NF-κB pathway by inhibiting the Trx system. Moreover, small molecules that mimic EM23 by simultaneously activating ROS-MAPK pro-apoptotic pathways and blocking anti-apoptotic NF-κB pathways may improve the outcomes of myeloid leukemia chemotherapy.

In summary, we showed the ability of EM23 to inhibit the proliferation of human myeloid leukemia K562 and HL-60 cells by inducing apoptosis via mitochondrial pathways. Suppression of the Trx system following treatment with EM23 could result in ROS accumulation and subsequently activate a number of Trx-dependent pathways, including the ASK1, p38, JNK and ERK MAPK pathways, which may contribute to EM23-mediated apoptosis (**Figure [8](#F8){ref-type="fig"}**). Furthermore, EM23 also effectively blocks TNF-α/NF-κB axis signaling, implying that EM23 has a potential role in preventing NF-κB-mediated anti-apoptotic pathways. This report represents the first comprehensive analysis of the cellular signaling events that are affected by treatment with EM23, a compound found in EM, in human myeloid leukemia cells. The findings contained here in detail a possible anticarcinogenic molecular mechanism for EM23.

![**EM23 mediation of intracellular signaling leading to apoptosis in human myeloid leukemia cells.** Key: black arrows, activation; black blocks, inhibition; double arrows, multiple signal transduction steps.](fphar-07-00077-g008){#F8}
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ASK1

:   apoptosis regulating-signal kinase 1

CCK-8

:   Cell Counting Kit-8

DAPI

:   4′,6-diamidino-2-phenylindole

DCFH-DA

:   2',7'-dichlorofluorescein diacetate

DMSO

:   dimethyl sulfoxide

EM

:   *Elephantopus mollis*

JC-1

:   5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl-imidacarbocyanine iodide

MAPK

:   mitogen-activated protein kinases

MMP

:   mitochondrial membrane potential

MTT

:   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

NAC

:   *N*-acetyl-[L]{.smallcaps}-cysteine

NF-κB

:   nuclear factor-κB

PI

:   propidium iodide

ROS

:   reactive oxygen species

TKIs

:   tyrosine kinase inhibitors

TNF-α

:   tumor necrosis factor alpha

Trx

:   thioredoxin

TrxR

:   thioredoxinreductase

TUNEL

:   terminal deoxynucleotidyltransferase-mediated dUTP nick-end labeling
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